Stock · Healthcare
JNJ Johnson & Johnson
Johnson & Johnson has a solid dividend profile with no major red flags in the snapshot data.
Why we rate it 7.2
- Yield of 2.22% is in the typical sustainable zone (2-4%)
- Payout ratio data not available
- Mega-cap scale (>$200B) — market dominance reduces dividend pressure
Where JNJ ranks
We compute the same 0–10 safety score across 147dividend-paying stocks and ETFs. Here's where JNJ lands inside that universe.
The universe is curated to the most-searched US dividend payers. We'll expand it as the data layer grows; sector percentiles only appear when we have at least 5 comparable peers.
How JNJ's safety score has moved
69 daily snapshots over the trailing 89 days · range 7.2–9.0
Every Infnits dividend safety score is computed from the same factors (yield zone, payout ratio, trend vs 5-year average, instrument type, size). The history above is recomputed directly from each day's fundamentals snapshot, so the line reflects how the underlying signals actually moved — not retroactive smoothing.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
How we score dividend safety
The Infnits Dividend Safety Score is a 0–10 rating derived from yield zone, payout ratio (when applicable), yield trend versus 5-year average, instrument type, and company size. Each factor is independently transparent — see the reasons above for exactly which factors contributed to JNJ's score.
For the full methodology including the in-app version that uses ETF look-through and historical cut data, see our methodology page.
This is educational, not investment advice.Dividend safety scores reflect a snapshot of public data on the "as of" date shown. Verify current data on the issuer's investor relations page or your brokerage before making decisions.
Frequently asked questions
Is JNJ's dividend safe?
Based on snapshot data — yield 2.22%, payout ratio —, instrument type stock — Infnits rates JNJ's dividend safety profile as solid (7.2/10). This is one signal, not a recommendation.
What is JNJ's current dividend yield?
JNJ has a current dividend yield of 2.22% as of June 19, 2026.
How is JNJ's safety score calculated?
The score combines yield zone (yields above 7% historically carry elevated cut risk), payout ratio (lower is safer), trend vs. 5-year average yield, instrument type (ETFs are inherently more diversified), and size (larger companies have more stable cash flows). Each factor is scored 0-2.5 and summed to a 0-10 result.
Where does this data come from?
Fundamentals are sourced from public market data and refreshed regularly. The "as of" date on each page reflects the snapshot used for the score. For real-time data, check the issuer's investor relations page or your brokerage.
Should I buy JNJ based on this score?
No — this is an educational score based on a handful of public signals, not investment advice. Use it as one input among many. For a portfolio-aware analysis with ETF look-through and personalized insights, install the Infnits app.
JNJ head-to-head comparisons
See JNJ compared side-by-side with the most-searched peer tickers — yield, safety, growth trend, expense ratio, and tax treatment.
Other dividend tickers
Track your full portfolio's dividend safety
Connect your brokerage in the Infnits app and get a portfolio-wide safety score with ETF look-through, concentration analysis, and AI-generated insights — updated daily.